Business Description
Allakos Inc
NAICS : 325412
SIC : 2834
ISIN : US01671P1003
Description
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.12 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.25 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 11.4 | |||||
| 3-Year EPS without NRI Growth Rate | 11.6 | |||||
| 3-Year FCF Growth Rate | 16.5 | |||||
| 3-Year Book Growth Rate | -46.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.34 | |||||
| 9-Day RSI | 33.59 | |||||
| 14-Day RSI | 36.91 | |||||
| 6-1 Month Momentum % | -35.96 | |||||
| 12-1 Month Momentum % | -67.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.92 | |||||
| Quick Ratio | 4.92 | |||||
| Cash Ratio | 4.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.2 | |||||
| Shareholder Yield % | 7.79 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -75.14 | |||||
| ROA % | -58.65 | |||||
| ROIC % | -245.19 | |||||
| ROC (Joel Greenblatt) % | -299.17 | |||||
| ROCE % | -68.12 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.55 | |||||
| Price-to-Tangible-Book | 0.55 | |||||
| EV-to-EBIT | 0.18 | |||||
| EV-to-EBITDA | 0.19 | |||||
| EV-to-Forward-EBITDA | -1.39 | |||||
| EV-to-FCF | 0.31 | |||||
| Price-to-Net-Current-Asset-Value | 0.89 | |||||
| Price-to-Net-Cash | 0.98 | |||||
| Earnings Yield (Greenblatt) % | 555.56 | |||||
| FCF Yield % | -125.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Allakos Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.983 | ||
| Beta | 0.18 | ||
| Volatility % | 87.39 | ||
| 14-Day RSI | 36.91 | ||
| 14-Day ATR (€) | 0.043349 | ||
| 20-Day SMA (€) | 1.101645 | ||
| 12-1 Month Momentum % | -67.99 | ||
| 52-Week Range (€) | 0.9258 - 4.969 | ||
| Shares Outstanding (Mil) | 87.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Allakos Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Allakos Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Allakos Inc Frequently Asked Questions
What is Allakos Inc(FRA:37Z)'s stock price today?
The current price of FRA:37Z is €0.98. The 52 week high of FRA:37Z is €4.97 and 52 week low is €0.93.
When is next earnings date of Allakos Inc(FRA:37Z)?
The next earnings date of Allakos Inc(FRA:37Z) is 2024-05-09 Est..
Does Allakos Inc(FRA:37Z) pay dividends? If so, how much?
Allakos Inc(FRA:37Z) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers